BioPlus Therapeutics - B(02315.HK)2025 Annual Revenue: 1.379 billion yuan, up 40.6%; Net profit: 173 million yuan, a surge of 416.4%

Gelonghui, March 26 — Baio Saiku-B (02315.HK) announced its 2025 annual results. Revenue reached 1.379 billion yuan, a year-on-year increase of approximately 40.6%. Net profit attributable to shareholders of the company for the year was 173 million yuan, a year-on-year increase of about 416.4%. Basic earnings per share were 0.43 yuan.

Since 2025, multiple factors have driven profound changes in the external environment. The overall macroeconomic situation has stabilized, improved, and continued to rebound, especially after the phased adjustment in the biopharmaceutical industry, which has entered a new stage of recovery and development. We remain committed to the strategic goal of “innovation-driven new drug research and development,” maintaining high-level R&D investment, and positioning ourselves in the global market. Our goal is to provide global biopharmaceutical companies with products and services that are both globally competitive and technologically advanced.

The company’s 2025 performance continues to improve, with rapid growth in operating revenue and a significant increase in net profit. Cash flow from operating activities has also shown high-level growth. Meanwhile, funds raised from the STAR Market listing have been received, significantly improving the capital structure. The company has officially entered a new stage of scaled profitability development.

Looking ahead to 2026, the company will enter a new phase of high-quality development. This year will be both a year of unity and pioneering effort for all Baio Saiku employees and a critical year for implementing our strategic plans. The company will continue to deepen its core strategies, upgrade its technology platforms and product systems, and aim to establish itself as a global hub for new drug innovation. We are committed to creating sustainable and stable returns for shareholders and contributing core strength to the development of the biopharmaceutical industry.